Fetal growth promoting effect of hydroxyethylrutoside in pregnant women

Abstract

ObjectiveTo evaluate the effect of hydroxyethylrutoside (HER) for fetal development because this flavonoid derivate drug is frequently used in pregnant women for the treatment of vascular diseases.MethodComparative analysis of exposure (HER treatment) during pregnancy in the newborn infants without any defects born to mothers with or without HER treatment in the population-based Hungarian Case-Control Surveillance System of Congenital Abnormalities. Main outcomes measures were gestational age at delivery, birth weight, pre- and post-term birth, low and large birth weight.ResultsOf 38,151 newborn infants, 1,143 (3.0%) were born to mothers with oral HER treatment. The mean birth weight of newborn infants born to mothers with HER was 115 grams larger and is associated with a lower rate of low birth weight and a higher rate of large birth weight.ConclusionsOral HER treatment during pregnancy associates with a fetal growth promotion effect.